SNS Insider Peptide Synthesis Market Report (May 19): Market Reaches $1.89B by 2035 — GLP-1 Demand Drives Bachem, PolyPeptide, CordenPharma SPPS Capacity Build-Out
SNS Insider published its 2026 Peptide Synthesis Market Report on Tuesday May 19, projecting the global peptide synthesis market to reach $1,889.88M by 2035 from current levels, anchored on GLP-1 receptor agonist demand and the broader peptide therapeutics pipeline. The report tracks the major SPPS capacity expansions: CordenPharma's $500M+ Boulder Colorado site adding 25,000L+ to reach 42,000L total by 2028, Bachem's three-site expansion (Bubendorf Switzerland, St Helens UK, Vista California) plus a new Sisseln Switzerland facility, and PolyPeptide's €200M credit facility supporting the doubling of 2023 revenue by 2028. The structural read: incretin-class peptide demand (semaglutide, tirzepatide, retatrutide, mazdutide, survodutide, eleglipron) plus the next-generation pipeline (NK2R agonists, amylin combos, peptide-drug conjugates) is the demand wave the CDMOs are positioning against.